GCM
TRVI icon

Graham Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Graham Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
+17,947
New +$261K 0.01% 861
2025
Q4 		– Sell
-49,043
Closed -$449K – 1586
2025
Q3 		$449K Buy
49,043
+8,982
+22% +$67.4K 0.01% 658
2025
Q2 		$219K Buy
+40,061
New +$249K ﹤0.01% 1097

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Graham Capital Management's TRVI Position: Q2 2026 in Review

Graham Capital Management opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 17,947 shares worth $335K. The stake represents 0.01% of the portfolio and ranks #861 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in TRVI as recently as Q3 2025.

Graham Capital Management first reported a position in TRVI in Q2 2025 and has held it in 3 quarters since. The position peaked at $449K in Q3 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Graham Capital Management held 17,947 shares of Trevi Therapeutics worth $335K as of Q2 2026.
  • Trevi Therapeutics was a new Graham Capital Management position in Q2 2026.
  • Trevi Therapeutics made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #861 holding.
  • Graham Capital Management first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Graham Capital Management's Trevi Therapeutics position peaked at $449K in Q3 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.